The Future Of Rebates: MedPAC Will Be Watching For Pricing Law Impacts
Executive Summary
The US Medicare Payment Advisory Commission is finally able to analyze the impact of rebates on actual prescription drug spending – but immediate recommendations may not be viable given the changes coming from implementation of the Inflation Reduction Act.
You may also be interested in...
Part D Cost Sharing Based On Net Price, Boost For ‘High Discount’ Biosimilars Proposed In Draft Bill
Senate Finance Committee’s PBM legislation would essentially pass through rebate value at the pharmacy counter for some drugs, block situations where beneficiaries pay more than plans and reward biosimilars that have list prices substantially below their reference products.
Part D Cost Sharing Based On Net Price, Boost For ‘High Discount’ Biosimilars Proposed In Draft Bill
Senate Finance Committee’s PBM legislation would essentially pass through rebate value at the pharmacy counter for some drugs, block situations where beneficiaries pay more than plans and reward biosimilars that have list prices substantially below their reference products.
Rebates In Part D: HHS Argues Scrutiny Of Impact On Formularies, Beneficiaries Not Needed Now
New GAO recommendations springing from recent Medicare Part D cost and access trends related to rebates may not be relevant going forward because the IRA price negotiation program and benefit redesign will significantly change the landscape, HHS says.